Skip to main content
Clinical Trials/NCT03304314
NCT03304314
Recruiting
Not Applicable

Assessment of Pupillary Response and Visual Field Defects by Objective Multifocal Chromatic Pupillometer in Patients With Pseudotumor Cerebri and Healthy Subjects

Sheba Medical Center1 site in 1 country100 target enrollmentNovember 3, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pseudotumor Cerebri
Sponsor
Sheba Medical Center
Enrollment
100
Locations
1
Primary Endpoint
Measurement of maximal velocity of pupil contraction and dilation in response to chromatic light stimulus
Status
Recruiting
Last Updated
6 months ago

Overview

Brief Summary

PTC(Pseudotumor cerebri) patients may develop increased Intracranial pressure (ICP) that can produces increased pressure around the distal optic nerve,which is likely followed by venule compression, ischemia, and loss of visual function.Vision loss in PTC is most commonly characterized by standard automated perimetry to measure peripheral visual field sensitivity.

Pupillometry is a promising approach for functional assessment in PTC because it is noninvasive, objective, performed quickly with minimal patient cooperation needed.

The feasibility of using chromatic multifocal pupillometry for assesment of PTC will be examined.

Registry
clinicaltrials.gov
Start Date
November 3, 2017
End Date
December 31, 2027
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Ygal Rotenstreich

Head of ElectrophisiologyClinic and Retinal Research Laboratory

Sheba Medical Center

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects
  • Male or female patients, age between 18 and 80 years, inclusive
  • Informed written consent will be obtained from all participants.
  • Normal eye examination
  • Best-corrected visual acuity (BCVA) of 20/20
  • Normal color vision test (Ishihara/HRR)
  • Normal Spectral-Domain Optical Coherence Tomography (SD-OCT)
  • Normal 24-2 Humphrey visual field (SITA Standard) and:
  • Short duration (≤10 minutes)
  • Minimal fixation losses, False POS errors and False NEG errors (less than 33% for each one of reliability indices)

Exclusion Criteria

  • Healthy subjects
  • History of past (last 3 months) or present ocular disease or ocular surgery
  • Use of any topical or systemic medications that could adversely influence pupillary reflex
  • Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tonometry or other schedule study procedure.
  • Mental impairment or instability such as that informed consent may not be obtained or compliance with tester instructions is unlikely.
  • Visual media opacity including cloudy corneas.
  • Any condition preventing accurate measurement or examination of the pupil.
  • PTC patients
  • Any other neurologic or ophthalmic disease other than PTC
  • Use of any topical or systemic medications that could adversely influence pupillary reflex

Outcomes

Primary Outcomes

Measurement of maximal velocity of pupil contraction and dilation in response to chromatic light stimulus

Time Frame: single visit: 1 day

Pupil contraction and dilation velocity (in pixel/second) in response to blue and red light displayed at 76 test targets in a visual field of 30 degree will be measured in PTC patients and compared to matched controls

Measurement of maximal precentage of pupil contraction and dilation in response to chromatic light stimulus

Time Frame: single visit: 1 day

Percentage of pupil contraction and dilation in response to blue and red light displayed at 76 test targets in a visual field of 30 degree will be measured in PTC patients and compared to matched controls

Measurement of latency of pupil contraction and dilation in response to chromatic light stimulus

Time Frame: single visit: 1 day

Pupil contraction and dilation latency (in seconds) in response to blue and red light displayed at 76 test targets in a visual field of 30 degree will be measured in PTC patients and compared to matched controls

Secondary Outcomes

  • Change from baseline pupil contraction and dilation precentage in PCT patients at 48 hours(single visit: 1 day, 48 hours after baseline testing)
  • Change from baseline pupil contraction and dilation latency in PCT patients at 2 months.(single visit: 1 day, 2 months after baseline testing)
  • Change from baseline pupil contraction and dilation latency in PCT patients at 48 hours(single visit: 1 day, 48 hours after baseline testing)
  • Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 2 months.(single visit: 1 day, 2 months after baseline testing)
  • Change from baseline pupil contraction and dilation precentage in PCT patients at 1 week.(single visit: 1 day, 1 week after baseline testing)
  • Change from baseline pupil contraction and dilation precentage in PCT patients at 2 months.(single visit: 1 day, 2 months after baseline testing)
  • Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 48 hours(single visit: 1 day, 48 hours after baseline testing)
  • Change from baseline pupil contraction and dilation latency in PCT patients at 1 week.(single visit: 1 day, 1 week after baseline testing)
  • Subjective visual field(single visit: 1 day)
  • Optic nerve structure by OCT(single visit: 1 day)
  • Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 1 week.(single visit: 1 day, 1 week after baseline testing)

Study Sites (1)

Loading locations...

Similar Trials